SND
MCID: SCK002
MIFTS: 55

Sick Sinus Syndrome (SND)

Categories: Cardiovascular diseases, Genetic diseases, Muscle diseases, Rare diseases

Aliases & Classifications for Sick Sinus Syndrome

MalaCards integrated aliases for Sick Sinus Syndrome:

Name: Sick Sinus Syndrome 12 25 36 54 6 43 15 71 32
Sinus Node Dysfunction 25 71
Sinus Node Disease 25 6
Sinus Node Infection 12
Sss 25
Snd 25

Classifications:



External Ids:

Disease Ontology 12 DOID:13884
KEGG 36 H00729
MeSH 43 D012804
NCIt 49 C62244
SNOMED-CT 67 36083008
ICD10 32 I49.5
UMLS 71 C0037052 C0428908

Summaries for Sick Sinus Syndrome

Genetics Home Reference : 25 Sick sinus syndrome (also known as sinus node dysfunction) is a group of related heart conditions that can affect how the heart beats. "Sick sinus" refers to the sino-atrial (SA) node, which is an area of specialized cells in the heart that functions as a natural pacemaker. The SA node generates electrical impulses that start each heartbeat. These signals travel from the SA node to the rest of the heart, signaling the heart (cardiac) muscle to contract and pump blood. In people with sick sinus syndrome, the SA node does not function normally. In some cases, it does not produce the right signals to trigger a regular heartbeat. In others, abnormalities disrupt the electrical impulses and prevent them from reaching the rest of the heart. Sick sinus syndrome tends to cause the heartbeat to be too slow (bradycardia), although occasionally the heartbeat is too fast (tachycardia). In some cases, the heartbeat rapidly switches from being too fast to being too slow, a condition known as tachycardia-bradycardia syndrome. Symptoms related to abnormal heartbeats can include dizziness, light-headedness, fainting (syncope), a sensation of fluttering or pounding in the chest (palpitations), and confusion or memory problems. During exercise, many affected individuals experience chest pain, difficulty breathing, or excessive tiredness (fatigue). Once symptoms of sick sinus syndrome appear, they usually worsen with time. However, some people with the condition never experience any related health problems. Sick sinus syndrome occurs most commonly in older adults, although it can be diagnosed in people of any age. The condition increases the risk of several life-threatening problems involving the heart and blood vessels. These include a heart rhythm abnormality called atrial fibrillation, heart failure, cardiac arrest, and stroke.

MalaCards based summary : Sick Sinus Syndrome, also known as sinus node dysfunction, is related to sick sinus syndrome 1 and sick sinus syndrome 3. An important gene associated with Sick Sinus Syndrome is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are Cardiac conduction and cGMP-PKG signaling pathway. The drugs Amiodarone and Propafenone have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and atrioventricular node, and related phenotypes are behavior/neurological and cardiovascular system

KEGG : 36 Sick sinus syndrome (SSS) comprises a variety of conditions involving sinus node dysfunction and commonly affects elderly persons. Patients may experience syncope, pre-syncope, palpitations, or dizziness. SSS has multiple manifestations on electrocardiogram, including sinus bradycardia, sinus arrest, sinoatrial block, and alternating patterns of bradycardia and tachycardia. Autosomal recessive type (SSS1) can be caused by compound heterozygous mutation in the SCN5A gene, and autosomal dominant type (SSS2) can be caused by heterozygous mutation in the HCN4. SCN5A encodes an alpha-subunit of the cardiac sodium channel carrying the current to form a rapid upstroke of action potential, whereas HCN4 codes for an alpha-subunit of hyperpolarization-activated cation channel.

Wikipedia : 74 Sick sinus syndrome (SSS), is a group of abnormal heart rhythms (arrhythmias) presumably caused by a... more...

Related Diseases for Sick Sinus Syndrome

Diseases in the Sick Sinus Syndrome family:

Sick Sinus Syndrome 2 Sick Sinus Syndrome 1
Sick Sinus Syndrome 3 Familial Sick Sinus Syndrome

Diseases related to Sick Sinus Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 364)
# Related Disease Score Top Affiliating Genes
1 sick sinus syndrome 1 35.1 SCN5A LOC110121269
2 sick sinus syndrome 3 35.1 MYH6 LOC114827851
3 familial sick sinus syndrome 34.7 SCN5A MYH6 HCN4 AGT
4 syncope 31.6 TTN SCN5A NPPA
5 atrioventricular block 30.8 TTN SCN5A LMNA HCN4 GJA5 CACNA1C
6 cardiac conduction defect 30.7 SCN5A SCN1B LMNA
7 progressive familial heart block, type ia 30.7 SCN5A GJA5 ANK2
8 first-degree atrioventricular block 30.6 SCN5A LMNA GJA5
9 right bundle branch block 30.5 SCN5A SCN1B RANGRF HCN4 CACNA1C
10 atrial standstill 30.4 SCN5A NPPA GJA5
11 congestive heart failure 30.4 TTN SCN5A NPPA MYH6 CACNA1C AGT
12 brugada syndrome 1 30.3 SCN5A SCN10A LOC110121269
13 second-degree atrioventricular block 30.3 SCN5A HCN4
14 familial isolated dilated cardiomyopathy 30.3 TTN SCN5A MYH6
15 familial long qt syndrome 30.2 SCN5A CACNA1C
16 cardiac arrhythmia 30.2 SCN5A RANGRF CACNA1C ANK2
17 mitral valve insufficiency 30.2 NPPA MYH6 MIR423
18 cardiac arrest 30.2 TTN SCN5A MYH6 HCN4 ANK2
19 cardiomyopathy, dilated, 1e 30.1 TTN SCN5A LMNA
20 restrictive cardiomyopathy 30.1 TTN MYH6 LMNA CACNA1C
21 wolff-parkinson-white syndrome 30.1 SCN5A MYH6 GJA5
22 pulmonary edema 30.1 NPPA F2 AGT
23 coronary artery anomaly 30.1 SCN5A NPPA MYH6 F2
24 ebstein anomaly 30.0 SCN5A MYH6 HCN4 GJA5
25 tetralogy of fallot 30.0 SCN5A NPPA MYH6 GJA5
26 diastolic heart failure 29.9 TTN NPPA AGT
27 sinoatrial node disease 29.9 SCN5A SCN1B RANGRF MYH6 HCN4 GJA5
28 heart septal defect 29.9 NPPA MYH6 MIR423 GJA5 F2
29 heart valve disease 29.8 TGFB1 NPPA MYH6 MIR423 F2
30 atrial heart septal defect 29.8 TTN SCN5A NPPA MYH6 GJA5 F2
31 hypertrophic cardiomyopathy 29.8 TTN SCN5A MYH6 LMNA HCN4 CACNA1C
32 muscular disease 29.8 TTN SCN5A MYH6 LMNA HCN4
33 holt-oram syndrome 29.7 NPPA MYH6 LMNA GJA5
34 mitral valve disease 29.7 NPPA MIR423 F2 AGT
35 third-degree atrioventricular block 29.5 TTN SCN5A SCN1B HCN4 GJA5
36 long qt syndrome 3 29.4 SNTA1 SCN5A SCN1B LOC110121269 CACNA1C ANK2
37 atrial standstill 1 29.4 TTN SCN5A SCN1B NPPA MYH6 LMNA
38 long qt syndrome 2 29.3 SNTA1 SCN5A SCN1B CACNA1C ANK2
39 short qt syndrome 29.3 SNTA1 SCN5A SCN1B CACNA1C ANK2
40 aortic valve disease 2 29.3 TTN NPPA MYH6 MIR423 AGT
41 arrhythmogenic right ventricular cardiomyopathy 29.2 TTN SCN5A MYH6 LMNA HCN4 CACNA1C
42 left ventricular noncompaction 28.8 TTN SNTA1 SCN5A MYH6 LOC114827851 LOC110121269
43 myocardial infarction 28.6 TGFB1 SCN5A NPPA MYH6 MIR423 F2
44 catecholaminergic polymorphic ventricular tachycardia 28.6 SNTA1 SCN5A SCN1B MYH6 LMNA HCN4
45 hypertension, essential 28.4 TGFB1 NPPA MYH6 MIR423 GJA5 F2
46 atrial fibrillation 28.3 TTN SCN5A SCN1B NPPA LMNA HCN4
47 long qt syndrome 28.3 TTN SNTA1 SCN5A SCN1B MYH6 LOC110121269
48 brugada syndrome 27.9 TTN SNTA1 SCN5A SCN1B SCN10A RANGRF
49 dilated cardiomyopathy 27.3 TTN TGFB1 SNTA1 SCN5A NPPA MYH6
50 heart disease 27.0 TTN TGFB1 SCN5A NPPA MYH6 MIR423

Graphical network of the top 20 diseases related to Sick Sinus Syndrome:



Diseases related to Sick Sinus Syndrome

Symptoms & Phenotypes for Sick Sinus Syndrome

MGI Mouse Phenotypes related to Sick Sinus Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 AGT CACNA1C F2 LMNA MYH6 SCN10A
2 cardiovascular system MP:0005385 9.73 AGT CACNA1C F2 GJA5 HCN4 LMNA
3 muscle MP:0005369 9.36 AGT CACNA1C GJA5 HCN4 LMNA MYH6

Drugs & Therapeutics for Sick Sinus Syndrome

Drugs for Sick Sinus Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
2
Propafenone Approved Phase 4 54063-53-5 4932
3
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
4
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
7
Atenolol Approved Phase 4 29122-68-7 2249
8
Ethanol Approved Phase 4 64-17-5 702
9
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
10
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
11
Bisoprolol Approved Phase 4 66722-44-9 2405
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13
Ticagrelor Approved Phase 4 274693-27-5 9871419
14
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
15
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
16 Angiotensinogen Phase 4
17 Angiotensin II Type 1 Receptor Blockers Phase 4
18 Angiotensin Receptor Antagonists Phase 4
19 Giapreza Phase 4
20 Cytochrome P-450 CYP3A Inhibitors Phase 4
21 Potassium Channel Blockers Phase 4
22 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
23 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
24 Natriuretic Agents Phase 4
25 diuretics Phase 4
26 Sodium Chloride Symporter Inhibitors Phase 4
27 Adrenergic Agonists Phase 4
28 Vasodilator Agents Phase 4
29 Adrenergic beta-Agonists Phase 4
30 Hydrocortisone hemisuccinate Phase 4
31 Hydrocortisone-17-butyrate Phase 4
32 Hydrocortisone 17-butyrate 21-propionate Phase 4
33 Anti-Inflammatory Agents Phase 4
34 Fibrinolytic Agents Phase 4
35 Analgesics, Non-Narcotic Phase 4
36 Platelet Aggregation Inhibitors Phase 4
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4
38 Cyclooxygenase Inhibitors Phase 4
39 Antipyretics Phase 4
40 Antirheumatic Agents Phase 4
41 Purinergic P2Y Receptor Antagonists Phase 4
42 Analgesics Phase 4
43 Tocolytic Agents Phase 4
44 Anti-Asthmatic Agents Phase 4
45 Respiratory System Agents Phase 4
46 Bronchodilator Agents Phase 4
47 Albuterol Phase 4
48 Anti-Arrhythmia Agents Phase 4
49 Adrenergic beta-Antagonists Phase 4
50 Antihypertensive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
2 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
3 IntAct, Study on Promotion of Intrinsic Activity. Unknown status NCT00156741 Phase 4
4 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
5 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
6 Prevention of Atrial Arrhythmia in Patients Without AV Conduction Disease Completed NCT01170611 Phase 4
7 Spontaneous Atrio Ventricular Conduction Preservation Completed NCT00655213 Phase 4
8 A Randomized, Prospective Multicenter Study to Examine the Optimal Position of the Atrial Leads for Therapy of the Sinus Node Syndrome Completed NCT00161538 Phase 4
9 The Impact of Heart Rate on Central Hemodynamics in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker Completed NCT03245996 Phase 4 Atenolol Pill;Nebivolol Pill;Ivabradine Pill
10 Analyse Der Unterschiede Zwischen Aktiv-fixierenden Und Passiv-fixierenden Stimulations-Elektroden Hinsichtlich Implantationsdauer Und Elektrischer Parameter Completed NCT00180557 Phase 4
11 Falls and Cardiovascular Events in Elderly Patients With Sinus Node Disease Treated With a MVPTM Pacemaker According to the ESC 2007 Guidelines Completed NCT01037426 Phase 4
12 Investigational New Drug Application/ Investigational Device Exemption Information Completed NCT00239226 Phase 4
13 Syncope: Pacing or Recording in the Later Years (SPRITELY) Completed NCT01423994 Phase 4
14 CLEAR: Cylos Pacemaker Responds With Physiologic Rate Changes During Daily Activities Completed NCT00355797 Phase 4
15 Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Completed NCT03800264 Phase 4 Bisoprolol
16 Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease Completed NCT02383771 Phase 4 Ticagrelor;Aspirin + Ticagrelor;Control;Aspirin + Ticagrelor
17 The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial Completed NCT02914652 Phase 4 Salbutamol;Norflouran (Placebo Evohaler(R) )
18 Beta-blockeRs tO patieNts With CHronIc Obstructive puLmonary diseasE Recruiting NCT03566667 Phase 4 Metoprolol;Standard care
19 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
20 EnPulse Trial on Search AV+ Influence Terminated NCT00157794 Phase 4
21 VIRTUE: Virtual Clinic Pacemaker Follow-up Terminated NCT00475124 Phase 4
22 Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension, Permanent Pacemakers and Risk Factors for Developing Atrial Fibrillation Unknown status NCT00225667 Phase 3 Irbesartan
23 Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. A Double-blind, Randomized, Parallel-group, Single Centre Study Unknown status NCT02909166 Phase 3 aliskiren
24 Phase 3, Prospective, Randomized, Double-blinded, Placebo-controlled Study to Evaluate Efficacy of add-on Therapy With Spironolactone to Reduce Diffuse Myocardial Fibrosis Thus Preventing Recurrent Episodes of Atrial Fibrillation in Patients With Paroxysmal or Persistent Atrial Fibrillation and Preserved Ejection Fraction Compared to Usual Care. Unknown status NCT02764619 Phase 3 Spironolactone;Placebo
25 Mode Selection Trial in Sinus Node Dysfunction (MOST) Completed NCT00000561 Phase 3
26 Increasing Atrial Base Rate Pacing to Reduce Atrial Fibrillation Completed NCT02317068 Phase 3
27 A Prospective Canadian Multi-Center Randomized Study; Spontaneous AtrioVEntricular Conduction PReservation Completed NCT01219621 Phase 3
28 Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Completed NCT00319982 Phase 2, Phase 3 Diltiazem;Placebo
29 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
30 Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients Recruiting NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
31 A Randomized Trial of Closed Loop Stimulation After Epicardial Pacemaker Implantation for Congenital Heart Disease Not yet recruiting NCT03361189 Phase 2, Phase 3
32 The Danish Multicenter Randomised Study on AAI Versus DDD Pacing in Sick Sinus Syndrome Terminated NCT00236158 Phase 2, Phase 3
33 Second Study on Cardio-neuromodulation in Humans Unknown status NCT02954666 Phase 2
34 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
35 Minimizing Right Ventricular Pacing in Dual-chamber Pacemaker Patients With Sinus Node Disease and First Degree Atrioventricular Block. Unknown status NCT01611389
36 Identification of Gene Polymorphism in Patients With Sick Sinus Syndrome in Chinese Population in Taiwan Unknown status NCT00314223
37 The Role of Angiotensinogen Gene Polymorphism in the Pathogenesis of Non-familial Sick Sinus Syndrome Unknown status NCT01310920
38 The Effect of Losartan on Atrial Fibrillation and Pacemaker Dependence in Sick Sinus Syndrome (SSS) Patients Receiving Physiological Pacemaker - A Prospective, Randomized, Multicenter Study in Taiwan Unknown status NCT00647257 Losartan;Placebo
39 Left Ventricular Function and Remodelling During Permanent Pacing Unknown status NCT00228241
40 Identify the Genes Polymorphisms Related to Non-familial Bradyarrhythmia Unknown status NCT01310907
41 Comparison of Right Ventricular Septal Pacing to Minimized Right Ventricular Septal Stimulation in Patients With Sick Sinus Syndrome Unknown status NCT01477138
42 Impact of Septal Vs Apical Pacing on Right and Left Ventricular Performance Unknown status NCT01798043
43 Left Ventricular Pacing to Prevent Iatrogenic Tricuspid Regurgitation Caused by Conventional Right Ventricular Pacing: a Pilot Study Unknown status NCT02314897
44 Right Ventricular Lead Placement in a Pacemaker Population: Evaluation of Apical and Alternative Position - Right Pace Study Unknown status NCT01647490
45 A Trial Comparing the Sensitivity and Specificity of Coronary Angiography With Coronary CT Angiography Unknown status NCT00146887
46 Perioperative Administration of COX 2 Inhibitors and Beta Blockers in Women Undergoing Breast Cancer Surgery: an Intervention to Decrease Immune Suppression, Metastatic Potential and Cancer Recurrence Unknown status NCT00502684 Propranolol, etodolac
47 INGEVITY(TM) Active Fixation and Passive Fixation Pace/ Sense Lead Clinical Study Completed NCT01688843
48 Clinical Observations of Automatic Algorithms for Cardiac Pacing Completed NCT00286858
49 Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction (SAVE PACe) Completed NCT00284830
50 A Comparison of Rate Response Performance in Pacemaker Patients With an Indication of Sinus Node Dysfunction. Completed NCT02027909

Search NIH Clinical Center for Sick Sinus Syndrome

Cochrane evidence based reviews: sick sinus syndrome

Genetic Tests for Sick Sinus Syndrome

Anatomical Context for Sick Sinus Syndrome

MalaCards organs/tissues related to Sick Sinus Syndrome:

40
Heart, Testes, Atrioventricular Node, Prostate, Brain, Lung, B Cells

Publications for Sick Sinus Syndrome

Articles related to Sick Sinus Syndrome:

(show top 50) (show all 3427)
# Title Authors PMID Year
1
The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. 61 6
18451998 2008
2
Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. 6
10377081 1999
3
Cardiac sodium channel Na(v)1.5 and interacting proteins: Physiology and pathophysiology. 54 61
19744495 2010
4
Sick sinus syndrome, progressive cardiac conduction disease, atrial flutter and ventricular tachycardia caused by a novel SCN5A mutation. 54 61
20395683 2010
5
Mouse models of SCN5A-related cardiac arrhythmias. 54 61
19041666 2008
6
A novel C-terminal truncation SCN5A mutation from a patient with sick sinus syndrome, conduction disorder and ventricular tachycardia. 54 61
17897635 2007
7
Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). 54 61
14523039 2003
8
[An intrapatient comparison of adaptation to aerobic and anaerobic exertion during 3 types of physiological cardiac stimulation in chronotropic failure of the sinus node: DDD, VVIR and DDDR]. 54 61
9118155 1997
9
[Secretion of atrial natriuretic peptide during artificial pacing: assessments including the influence of ventriculoatrial conduction]. 54 61
1307573 1992
10
Evaluation of cardiac synchrony in left bundle branch pacing: Insights from echocardiographic research. 61
31919928 2020
11
Genetic arrhythmias complicating patients with dilated cardiomyopathy. 61
31521807 2020
12
Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). 61
31911261 2020
13
Sick Sinus Syndrome: Sinus Node Dysfunction in the Elderly. 61
31939855 2020
14
Repair of Superior Sinus Venosus Atrial Septal Defect Using a Modified Two-Patch Technique. 61
31472131 2020
15
Robotic repair of partial anomalous pulmonary venous connection: the initial experience and technical details. 61
30828770 2020
16
Muscle weakness and impaired motor coordination in hyperpolarization-activated cyclic nucleotide-gated potassium channel 1-deficient rats. 61
31292305 2020
17
Cardiomyopathy associated with the Ala143Thr variant of the α-galactosidase A gene. 61
31949022 2020
18
Mechanisms and Alterations of Cardiac Ion Channels Leading to Disease: Role of Ankyrin-B in Cardiac Function. 61
32023981 2020
19
Usefulness of an Implantable Loop Recorder in Diagnosing Unexplained Syncope and Predictors for Pacemaker Implantation. 61
31920017 2020
20
Delayed diagnosis of short QT syndrome concealed by pacemaker implant due to sick sinus syndrome. 61
32011326 2020
21
Lyme carditis presenting as sick sinus syndrome. 61
32007907 2020
22
[Myotonic dystrophy type 1 - a rare cause of bradycardia in the young]. 61
31961442 2020
23
Outcomes of the Warden Procedure for Partial Anomalous Pulmonary Venous Drainage. 61
31811329 2020
24
In silico study of the effects of anti-arrhythmic drug treatment on sinoatrial node function for patients with atrial fibrillation. 61
31941982 2020
25
Outcomes of Double-patch and Warden Techniques in Patients With Supracardiac Partial Anomalous Pulmonary Venous Connection. 61
30686643 2020
26
Initial experience with ablation of the innervation surrounding sinus and atrioventricular nodes to treat paroxysmal bradyarrhythmia. 61
31880742 2020
27
Risk factors and survival of patients with permanent pacemaker implantation after heart transplantation. 61
32030263 2019
28
Permanent atrial fibrillation in patients with a dual‑chamber pacemaker. 61
31527561 2019
29
Left bundle branch pacing for symptomatic bradycardia: Implant success rate, safety, and pacing characteristics. 61
31125667 2019
30
A pacemaker lead in the left ventricle: An "unexpected" finding? 61
31762840 2019
31
Severe congenital RYR1-associated myopathy complicated with atrial tachycardia and sinus node dysfunction: a case report. 61
31856875 2019
32
Prospective evaluation of feasibility and electrophysiologic and echocardiographic characteristics of left bundle branch area pacing. 61
31136869 2019
33
Loss of Pacer Spikes as electrocardiographic (EKG) Artifact Due to Microdebrider Use During Endoscopic Dacryocystorhinostomy. 61
31880683 2019
34
Immediate and long-term need for permanent cardiac pacing following aortic valve replacement. 61
31809597 2019
35
Neonates and infants requiring life-long cardiac pacing: How reliable are epicardial leads through childhood? 61
31630820 2019
36
Permanent Pacemaker Implantations after Catheter Ablation in Patients with Atrial Fibrillation Associated with Underlying Sinus Node Dysfunction. 61
31960638 2019
37
Evaluation of a near-zero fluoroscopic approach for catheter ablation in patients with congenital heart disease. 61
30377927 2019
38
Heart rate variability in sick sinus syndrome: does it have a diagnostic role? 61
31625705 2019
39
A sexy approach to pacemaking: differences in function and molecular make up of the sinoatrial node. 61
30968943 2019
40
Glucocorticoid-sensitive Paroxysmal Atrial Fibrillation, Sick Sinus Syndrome, and Mitral Regurgitation in a Patient with Malignant Rheumatoid Vasculitis. 61
31292399 2019
41
The expanding phenotypes of cohesinopathies: one ring to rule them all! 61
31516082 2019
42
Spanish Pacemaker Registry. 16th Official Report of the Spanish Society of Cardiology Working Group on Cardiac Pacing (2018). 61
31631049 2019
43
Exome reports A de novo GNB2 variant associated with global developmental delay, intellectual disability, and dysmorphic features. 61
31698099 2019
44
When two hearts do not beat as one - An unusual cause of pacemaker related tachycardia. 61
31442564 2019
45
Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation. 61
31701215 2019
46
Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndrome. 61
31751569 2019
47
Syncope due to unexpected paroxysmal sinus arrest. 61
31765961 2019
48
An unusual pacing artifact. 61
31582675 2019
49
Voltage mapping to guide pacemaker placement in patients with CHD. 61
31475646 2019
50
Sick Sinus Syndrome: Sinus Node Dysfunction in the Elderly. 61
31625958 2019

Variations for Sick Sinus Syndrome

ClinVar genetic disease variations for Sick Sinus Syndrome:

6 (show top 50) (show all 112) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SCN5A NM_198056.2(SCN5A):c.3893C>T (p.Pro1298Leu)SNV Pathogenic 9394 rs28937319 3:38603976-38603976 3:38562485-38562485
2 SCN5A NM_198056.2(SCN5A):c.5350G>A (p.Glu1784Lys)SNV Pathogenic/Likely pathogenic 9377 rs137854601 3:38592513-38592513 3:38551022-38551022
3 SCN5A NM_198056.2(SCN5A):c.3308C>A (p.Ser1103Tyr)SNV risk factor 9393 rs7626962 3:38620907-38620907 3:38579416-38579416
4 SCN5A NM_198056.2(SCN5A):c.1252G>T (p.Glu418Ter)SNV Likely pathogenic 222805 rs869025519 3:38647528-38647528 3:38606037-38606037
5 SCN5A NM_198056.2(SCN5A):c.4437+13C>TSNV Conflicting interpretations of pathogenicity 36762 rs148598985 3:38597919-38597919 3:38556428-38556428
6 SCN5A NM_198056.2(SCN5A):c.2436+12G>ASNV Conflicting interpretations of pathogenicity 36758 rs41312419 3:38628879-38628879 3:38587388-38587388
7 SCN5A NM_198056.2(SCN5A):c.1681C>T (p.Leu561=)SNV Conflicting interpretations of pathogenicity 48290 rs45522138 3:38645412-38645412 3:38603921-38603921
8 SCN5A NM_198056.2(SCN5A):c.5607C>T (p.Asp1869=)SNV Conflicting interpretations of pathogenicity 227933 rs560476223 3:38592256-38592256 3:38550765-38550765
9 SCN5A NM_198056.2(SCN5A):c.1068T>C (p.Asp356=)SNV Conflicting interpretations of pathogenicity 165156 rs41313703 3:38648232-38648232 3:38606741-38606741
10 SCN5A NM_198056.2(SCN5A):c.4824C>T (p.Leu1608=)SNV Conflicting interpretations of pathogenicity 165135 rs45437099 3:38593039-38593039 3:38551548-38551548
11 SCN5A NM_198056.2(SCN5A):c.6003C>T (p.Leu2001=)SNV Conflicting interpretations of pathogenicity 179813 rs538707712 3:38591860-38591860 3:38550369-38550369
12 SCN5A NM_198056.2(SCN5A):c.1569T>A (p.Arg523=)SNV Conflicting interpretations of pathogenicity 165155 rs41313693 3:38645524-38645524 3:38604033-38604033
13 SCN5A NM_198056.2(SCN5A):c.2151G>A (p.Pro717=)SNV Conflicting interpretations of pathogenicity 345125 rs191840835 3:38639331-38639331 3:38597840-38597840
14 SCN5A NM_198056.2(SCN5A):c.687T>C (p.Thr229=)SNV Conflicting interpretations of pathogenicity 345129 rs770390440 3:38655250-38655250 3:38613759-38613759
15 SCN5A NM_198056.2(SCN5A):c.2181C>T (p.Ile727=)SNV Conflicting interpretations of pathogenicity 345124 rs186942072 3:38639301-38639301 3:38597810-38597810
16 SCN5A NM_198056.2(SCN5A):c.2988C>T (p.Ala996=)SNV Conflicting interpretations of pathogenicity 345121 rs781529391 3:38622662-38622662 3:38581171-38581171
17 SCN5A NM_198056.2(SCN5A):c.2259C>T (p.Asn753=)SNV Conflicting interpretations of pathogenicity 345123 rs878911306 3:38639223-38639223 3:38597732-38597732
18 SCN5A NM_198056.2(SCN5A):c.1800G>A (p.Val600=)SNV Conflicting interpretations of pathogenicity 345127 rs758101066 3:38645293-38645293 3:38603802-38603802
19 SCN5A NM_198056.2(SCN5A):c.3228+6C>GSNV Conflicting interpretations of pathogenicity 345120 rs368048551 3:38622416-38622416 3:38580925-38580925
20 SCN5A NM_198056.2(SCN5A):c.3391-7T>CSNV Conflicting interpretations of pathogenicity 345118 rs41310769 3:38618279-38618279 3:38576788-38576788
21 SCN5A NM_198056.2(SCN5A):c.5286C>T (p.Ile1762=)SNV Conflicting interpretations of pathogenicity 345114 rs375323548 3:38592577-38592577 3:38551086-38551086
22 SCN5A NM_198056.2(SCN5A):c.5454C>T (p.Ala1818=)SNV Conflicting interpretations of pathogenicity 242203 rs370114378 3:38592409-38592409 3:38550918-38550918
23 SCN5A NM_198056.2(SCN5A):c.3873G>A (p.Leu1291=)SNV Conflicting interpretations of pathogenicity 139061 rs41313033 3:38603996-38603996 3:38562505-38562505
24 SCN5A NM_198056.2(SCN5A):c.2437-5C>ASNV Conflicting interpretations of pathogenicity 139054 rs72549411 3:38627537-38627537 3:38586046-38586046
25 SCN5A NM_198056.2(SCN5A):c.1743G>A (p.Ser581=)SNV Conflicting interpretations of pathogenicity 139051 rs41313687 3:38645350-38645350 3:38603859-38603859
26 SCN5A NM_198056.2(SCN5A):c.1044C>T (p.Pro348=)SNV Conflicting interpretations of pathogenicity 139044 rs370346797 3:38648256-38648256 3:38606765-38606765
27 SCN5A NM_198056.2(SCN5A):c.21T>A (p.Pro7=)SNV Conflicting interpretations of pathogenicity 139038 rs587781157 3:38674778-38674778 3:38633287-38633287
28 SCN5A NM_198056.2(SCN5A):c.3363G>A (p.Ala1121=)SNV Conflicting interpretations of pathogenicity 48300 rs9858585 3:38620852-38620852 3:38579361-38579361
29 SCN5A NM_198056.2(SCN5A):c.*1602G>TSNV Uncertain significance 345073 rs886058444 3:38590210-38590210 3:38548719-38548719
30 SCN5A NM_198056.2(SCN5A):c.*1701G>TSNV Uncertain significance 345070 rs886058441 3:38590111-38590111 3:38548620-38548620
31 SCN5A NM_198056.2(SCN5A):c.*980C>ASNV Uncertain significance 345086 rs886058449 3:38590832-38590832 3:38549341-38549341
32 SCN5A NM_198056.2(SCN5A):c.*1164G>TSNV Uncertain significance 345081 rs41315489 3:38590648-38590648 3:38549157-38549157
33 SCN5A NM_198056.2(SCN5A):c.*73C>ASNV Uncertain significance 345109 rs886058458 3:38591739-38591739 3:38550248-38550248
34 SCN5A NM_198056.2(SCN5A):c.*204T>CSNV Uncertain significance 345105 rs147795595 3:38591608-38591608 3:38550117-38550117
35 SCN5A NM_198056.2(SCN5A):c.*290G>ASNV Uncertain significance 345104 rs886058457 3:38591522-38591522 3:38550031-38550031
36 SCN5A NM_198056.2(SCN5A):c.*382T>CSNV Uncertain significance 345101 rs45459402 3:38591430-38591430 3:38549939-38549939
37 SCN5A NM_198056.2(SCN5A):c.*889C>ASNV Uncertain significance 345091 rs546849670 3:38590923-38590923 3:38549432-38549432
38 SCN5A NM_198056.2(SCN5A):c.*1074C>GSNV Uncertain significance 345083 rs776171341 3:38590738-38590738 3:38549247-38549247
39 SCN5A NM_198056.2(SCN5A):c.*1087G>ASNV Uncertain significance 345082 rs886058446 3:38590725-38590725 3:38549234-38549234
40 SCN5A NM_198056.2(SCN5A):c.*1390A>GSNV Uncertain significance 345079 rs41310753 3:38590422-38590422 3:38548931-38548931
41 SCN5A NM_198056.2(SCN5A):c.*1443C>ASNV Uncertain significance 345078 rs886058445 3:38590369-38590369 3:38548878-38548878
42 SCN5A NM_198056.2(SCN5A):c.*1496T>GSNV Uncertain significance 345076 rs41313015 3:38590316-38590316 3:38548825-38548825
43 SCN5A NM_198056.2(SCN5A):c.*1705C>TSNV Uncertain significance 345069 rs886058440 3:38590107-38590107 3:38548616-38548616
44 SCN5A NM_198056.2(SCN5A):c.*1731G>CSNV Uncertain significance 345068 rs569249327 3:38590081-38590081 3:38548590-38548590
45 SCN5A NM_198056.2(SCN5A):c.*1943C>ASNV Uncertain significance 345064 rs569552176 3:38589869-38589869 3:38548378-38548378
46 SCN5A NM_198056.2(SCN5A):c.*1969C>TSNV Uncertain significance 345063 rs190416544 3:38589843-38589843 3:38548352-38548352
47 SCN5A NM_198056.2(SCN5A):c.*2135C>ASNV Uncertain significance 345062 rs45502793 3:38589677-38589677 3:38548186-38548186
48 SCN5A NM_198056.2(SCN5A):c.2815C>T (p.Leu939Phe)SNV Uncertain significance 345122 rs886058462 3:38622835-38622835 3:38581344-38581344
49 SCN5A NM_198056.2(SCN5A):c.4827G>A (p.Ser1609=)SNV Uncertain significance 345115 rs886058460 3:38593036-38593036 3:38551545-38551545
50 SCN5A NM_198056.2(SCN5A):c.5971C>T (p.Arg1991Trp)SNV Uncertain significance 345112 rs371308670 3:38591892-38591892 3:38550401-38550401

Expression for Sick Sinus Syndrome

Search GEO for disease gene expression data for Sick Sinus Syndrome.

Pathways for Sick Sinus Syndrome

Pathways related to Sick Sinus Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.49 TTN SCN5A SCN1B SCN10A RANGRF NPPA
2
Show member pathways
12.34 SCN5A SCN1B NPPA MYH6 CACNA1C AGT
3
Show member pathways
12 TTN TGFB1 MYH6 LMNA CACNA1C AGT
4
Show member pathways
11.8 SCN5A SCN1B SCN10A ANK2
5 11.47 NPPA CACNA1C AGT
6 11.33 TGFB1 SCN5A MYH6
7
Show member pathways
11.23 SCN5A SCN1B SCN10A RANGRF CACNA1C
8 11.1 SCN5A SCN1B SCN10A ANK2
9 10.92 SCN5A SCN1B LMNA HCN4 GJA5 CACNA1C

GO Terms for Sick Sinus Syndrome

Cellular components related to Sick Sinus Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sarcolemma GO:0042383 9.62 SNTA1 SCN5A CACNA1C ANK2
2 Z disc GO:0030018 9.55 TTN SCN5A MYH6 CACNA1C ANK2
3 voltage-gated sodium channel complex GO:0001518 9.43 SCN5A SCN1B SCN10A
4 T-tubule GO:0030315 9.26 SCN5A SCN1B CACNA1C ANK2
5 intercalated disc GO:0014704 9.02 SCN5A SCN1B RANGRF GJA5 ANK2

Biological processes related to Sick Sinus Syndrome according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 regulation of ion transmembrane transport GO:0034765 9.92 SCN5A SCN1B SCN10A HCN4 CACNA1C
2 sodium ion transport GO:0006814 9.91 SCN5A SCN1B SCN10A HCN4
3 muscle contraction GO:0006936 9.88 TTN SNTA1 MYH6 HCN4
4 female pregnancy GO:0007565 9.85 TGFB1 NPPA AGT
5 sodium ion transmembrane transport GO:0035725 9.85 SCN5A SCN1B SCN10A HCN4
6 cellular response to mechanical stimulus GO:0071260 9.84 TGFB1 NPPA AGT
7 regulation of blood pressure GO:0008217 9.82 NPPA MYH6 AGT
8 cardiac conduction GO:0061337 9.81 SCN5A SCN1B GJA5 CACNA1C
9 cardiac muscle contraction GO:0060048 9.8 TTN SCN5A SCN1B MYH6
10 regulation of cardiac muscle contraction GO:0055117 9.73 SCN10A HCN4 GJA5 ANK2
11 cardiac muscle cell action potential involved in contraction GO:0086002 9.71 SCN5A SCN1B CACNA1C
12 ventricular cardiac muscle cell action potential GO:0086005 9.71 SNTA1 SCN5A GJA5 ANK2
13 positive regulation of cellular protein metabolic process GO:0032270 9.69 TGFB1 AGT
14 membrane depolarization during action potential GO:0086010 9.69 SCN5A SCN10A
15 cell growth involved in cardiac muscle cell development GO:0061049 9.69 NPPA AGT
16 positive regulation of sodium ion transport GO:0010765 9.68 SCN5A SCN1B
17 striated muscle contraction GO:0006941 9.68 TTN MYH6
18 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.68 GJA5 CACNA1C
19 cardiac muscle hypertrophy in response to stress GO:0014898 9.68 NPPA MYH6
20 regulation of cardiac muscle cell contraction GO:0086004 9.67 SCN5A ANK2
21 cardiac muscle fiber development GO:0048739 9.67 TTN MYH6
22 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.67 SCN5A SCN1B HCN4 CACNA1C
23 atrial cardiac muscle cell action potential GO:0086014 9.66 SCN5A ANK2
24 regulation of cardiac muscle cell action potential involved in regulation of contraction GO:0098909 9.65 RANGRF HCN4
25 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.65 SCN5A GJA5
26 regulation of membrane depolarization GO:0003254 9.65 RANGRF HCN4
27 regulation of sodium ion transmembrane transport GO:1902305 9.65 SNTA1 SCN5A RANGRF
28 atrial septum development GO:0003283 9.64 GJA5 ANK2
29 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.63 SCN5A NPPA
30 membrane depolarization during AV node cell action potential GO:0086045 9.63 SCN5A CACNA1C
31 membrane depolarization during SA node cell action potential GO:0086046 9.63 SCN5A HCN4 ANK2
32 regulation of membrane depolarization during cardiac muscle cell action potential GO:1900825 9.62 RANGRF GJA5
33 AV node cell action potential GO:0086016 9.62 SCN5A SCN10A
34 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 9.62 SCN5A SCN1B SCN10A GJA5
35 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.61 SCN5A CACNA1C
36 regulation of atrial cardiac muscle cell action potential GO:0098910 9.6 GJA5 ANK2
37 AV node cell to bundle of His cell communication GO:0086067 9.59 SCN5A GJA5
38 membrane depolarization during Purkinje myocyte cell action potential GO:0086047 9.58 SCN5A SCN1B
39 regulation of bundle of His cell action potential GO:0098905 9.57 RANGRF GJA5
40 bundle of His cell action potential GO:0086043 9.56 SCN5A SCN10A
41 SA node cell action potential GO:0086015 9.56 SCN5A HCN4 GJA5 ANK2
42 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.55 SNTA1 SCN5A SCN1B GJA5 ANK2
43 regulation of heart rate by cardiac conduction GO:0086091 9.43 SCN5A SCN1B HCN4 GJA5 CACNA1C ANK2
44 regulation of heart rate GO:0002027 9.23 SNTA1 SCN5A SCN10A RANGRF MYH6 HCN4

Molecular functions related to Sick Sinus Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.73 SCN5A SCN10A HCN4 CACNA1C
2 calmodulin binding GO:0005516 9.72 TTN SNTA1 SCN5A MYH6 CACNA1C
3 voltage-gated ion channel activity GO:0005244 9.65 SCN5A SCN1B SCN10A HCN4 CACNA1C
4 sodium channel regulator activity GO:0017080 9.58 SNTA1 SCN1B RANGRF
5 nitric-oxide synthase binding GO:0050998 9.48 SNTA1 SCN5A
6 voltage-gated sodium channel activity involved in cardiac muscle cell action potential GO:0086006 9.46 SCN5A SCN1B
7 sodium channel activity GO:0005272 9.46 SCN5A SCN1B SCN10A HCN4
8 voltage-gated sodium channel activity involved in Purkinje myocyte action potential GO:0086062 9.37 SCN5A SCN1B
9 voltage-gated sodium channel activity GO:0005248 9.26 SCN5A SCN1B SCN10A HCN4
10 ion channel binding GO:0044325 9.1 SNTA1 SCN5A SCN1B SCN10A RANGRF ANK2

Sources for Sick Sinus Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....